ABSTRACT SUBMISSION DEADLINE: Monday, February 2, 2015
NOTIFICATION OF ACCEPTANCE DEADLINE: Wednesday, February 4, 2015
Requirements for Submission
Authors must register for the conference before submitting an abstract. Upon successful registration, a confirmation number will be e-mailed to the address provided on the registration form.
How to Submit: The registration confirmation number, author name, author email, and the abstract submission document must be submitted via email to firstname.lastname@example.org
. By submitting your abstract, you are confirming the originality and authenticity of the data being presented.
Confirmation: Upon successful submission, an email confirmation will be sent to the author.
All abstracts will be reviewed in a blinded review process. Originality of work, adequacy of data, and clarity of exposition are the determinants used in the selection of abstracts for presentation. The Scientific Organizing Committee Chair will make the final decision with respect to the selection of any abstract. Authors will be notified via e-mail if their abstract is accepted or rejected.
The poster session is designed to allow for direct interaction and significant exchange of ideas between participants. Posters will be on display for the duration of the symposium with the poster session taking place the evening of March 2. Instructions on poster set up at the conference site will be e-mailed to the presenting authors the week of February 2.
Scientific Achievement Award
Authors of the top abstracts will be presented with the Rachmiel Levine Symposium Scientific Achievement Award and be invited to provide an oral presentation during the general session. Winning authors will be notified prior to the conference start date and MUST BE present to accept their award.
Publication of Abstracts
Abstracts may be revised up until the abstract submission deadline date. Final abstracts will be printed as submitted in the conference Program and Abstract Book. Changes to abstracts will not be accepted after publication and therefore should be carefully written and edited prior to submission. Abstracts accepted for presentation may also be published in special proceedings of the Rachmiel Levine Symposium and posted on the conference web site.
Length: Size limit for abstracts is 250 words or 1,500 characters, excluding the abstract title, authors’ names and affiliations. Any characters in a table and/or figure will count towards the size limit.
Format: All documents must be submitted as a Word Document (.doc/.docx) or Rich Text Form (.rtf). Adobe PDF Files(.pdf) will not be accepted.
Abstract Title: The abstract title should be in UPPER CASE BOLD. Do not use subtitles (e.g., Methods, Results) in the abstract body.
Author: Author(s)' complete first and last name(s) should be listed in Title Case. The name of the presenting author should be Underlined. If an author appears on more than one abstract the name should be listed the same way on all. Do not list credentials, degrees, academic title(s) (e.g., MD, RN).
Affiliation: Include departments, division, institutional affiliation(s), city and state (postal abbreviations) or country of origin of work. Do not include street address and zip code. Affiliation(s) should be listed in Title Case italic.
REGULATION OF INSULIN RECEPTOR SIGNALING PATHWAYS
John Jones1, Jane A. Doe, Adam Smith, Mary Brown2
1 Department of Endocrinology and 2 Department of Immunology, City of Hope, Duarte, CA
Body: Abstracts must be as informative as possible, including a brief statement of the purpose of the study or why it was done, the methods used, the results observed, and the author(s)' conclusions based upon the results. Actual data should be summarized. It is inadequate to state "The results will be discussed" or "The data will be presented."
Use of standard abbreviations is requested. Examples include kg, g, mg, mL, L (liter), m (meter), / (per), and % (percent). Place a special or unusual abbreviation in parentheses after the full word the first time it appears, then use the abbreviation throughout the rest of the abstract. Use numerals to indicate numbers, except when beginning a sentence.
Nonproprietary (generic) names should be used the first time a drug is mentioned and typed in lowercase letters; names are always capitalized, for example, aspirin (Bufferin).
Do not include references, credits, or grant support information in the abstract.
Tables, Figures or Graphics: Tables and graphics may be used to present data and will count towards the character limit.
Authors who wish to withdraw their abstract, must notify the Program Coordinator in writing. No fees will be refunded as a result of abstract withdrawal.